NF-1, Nutraceutical Intervention

Description

The treatment plan is identical for all participants with the exception of the curcumin dose level that is assigned at study enrollment. Participants are instructed to take the curcumin and olive oil one after the other (order does not matter) twice a day on an empty stomach ideally 30 minutes before breakfast and dinner. Curcumin and high phenolic extra virgin olive oil (HP-EVOO) may continue for up to 12 months in the absence of unacceptable side effects.

Conditions

Neurofibromatosis 1

Talk to us

Study Overview

On this page

Study Details

Study overview

The treatment plan is identical for all participants with the exception of the curcumin dose level that is assigned at study enrollment. Participants are instructed to take the curcumin and olive oil one after the other (order does not matter) twice a day on an empty stomach ideally 30 minutes before breakfast and dinner. Curcumin and high phenolic extra virgin olive oil (HP-EVOO) may continue for up to 12 months in the absence of unacceptable side effects.

Study of Nutraceutical Intervention With High Phenolic Extra Virgin Olive Oil and Curcumin for Neurofibromatosis, Type 1 (NF1)

NF-1, Nutraceutical Intervention

Condition
Neurofibromatosis 1
Intervention / Treatment

-

Contacts and Locations

Minneapolis

Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States, 55455

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * NF1 diagnosis based on NIH Consensus Conference Criteria and/or genetic testing
  • * Measurable cutaneous neurofibromas (cNFs) with or without plexiform NF
  • * Aged 18 years or older at the time of written consent
  • * Voluntary signed written consent obtained before the performance of any study-related procedure not part of normal medical care
  • * Concurrent treatment with selumetinib or other MAPK, MEK or mTOR inhibitors, other targeted therapies, chemotherapy or radiation
  • * Conditions requiring systemic immunosuppression
  • * Swallowing difficulties or strong gag reflex which may interfere with study compliance
  • * Any comorbidities that may affect study participation in the judgement of enrolling investigator
  • * Psychiatric illness, cognitive challenges, social situations, or other circumstances that would limit compliance with study requirements, per judgment of the enrolling investigator
  • * Treatment with high phenolic olive oil or curcumin within six months of study entry
  • * Known pregnancy or anticipated conception during the 1 year study period

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Masonic Cancer Center, University of Minnesota,

Christopher Moertel, MD, PRINCIPAL_INVESTIGATOR, Masonic Cancer Center, Univeristy of Minnesota

Study Record Dates

2026-08